Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products.
Gross profit (Q3, 2019)
Gross profit margin (Q3, 2019), %
Net income (Q3, 2019)
EBIT (Q3, 2019)
Market capitalization (14-Feb-2020)
Closing stock price (14-Feb-2020)
|USD||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019|
Depreciation and Amortization
|Company Name||Date||Deal Size|
|Zavante Therapeutics Inc||July 25, 2018||$124 m|
When was Nabriva Therapeutics founded?
Nabriva Therapeutics was founded in 2001.
Who are Nabriva Therapeutics key executives?
Nabriva Therapeutics's key executives are Denise Pollard-Knight.
How many employees does Nabriva Therapeutics have?
Nabriva Therapeutics has 110 employees.
What is Nabriva Therapeutics revenue?
Latest Nabriva Therapeutics annual revenue is $9.7 m.
What is Nabriva Therapeutics revenue per employee?
Latest Nabriva Therapeutics revenue per employee is $87.8 k.
Who are Nabriva Therapeutics competitors?
Competitors of Nabriva Therapeutics include NovaBay Pharmaceuticals, LGC Biosearch Technologies and Keryx Biopharmaceuticals.
Where is Nabriva Therapeutics headquarters?
Nabriva Therapeutics headquarters is located at Leberstrasse 20, Wien.
Where are Nabriva Therapeutics offices?
Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin and Dublin 1.
How many offices does Nabriva Therapeutics have?
Nabriva Therapeutics has 4 offices.
Receive alerts for 300+ data fields across thousands of companies